SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc. is pleased to announce the completion of the dose selection stage (Stage I) of the ADVENT trial of crofelemer for the treatment of chronic diarrhea in people living with HIV/AIDS on antiretroviral therapies. Up to 30 percent of the one million people living with HIV in the United States are managing diarrhea chronically. Crofelemer is a first-in-class anti-secretory agent that acts locally in the gastrointestinal tract. Napo focuses on the development and commercialization of proprietary pharmaceuticals in the global marketplace in collaboration with local partners.
